Drugs / OZORALIZUMAB
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00916110 | Nov 2008 → Nov 2009 | — | Ablynx, a Sanofi company | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT01007175 | Nov 2009 → Sep 2010 | rheumatoid arthritis | Ablynx, a Sanofi company | Completed | No outcome recorded |
| Phase 1/2 | NCT00959036 | Sep 2009 → Jan 2011 | rheumatoid arthritis | Ablynx, a Sanofi company | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT01063803 | Feb 2010 → Feb 2012 | rheumatoid arthritis | Ablynx, a Sanofi company | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | OZORALIZUMAB | ChEMBL registry synonym — accepted as the source's own label CHEMBL1743054 ↗ |
| Known as | ATN-103 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01007175 ↗ |
| Action | Inhibit | “TNF-alpha inhibitor” CHEMBL1743054 ↗ |
| Modality | Monoclonal antibody | — CHEMBL1743054 ↗ |
| Route | Subcutaneous | “1.5 mg solution, single subcutaneous injection” NCT00916110 ↗ |
| Target | TNF | “TNF-alpha inhibitor” CHEMBL1743054 ↗ |